Olema Pharmaceuticals (OLMA) Profit After Tax (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Profit After Tax data on file, last reported at -$53.1 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 74.7% year-over-year to -$53.1 million in Q1 2026; TTM through Mar 2026 was -$185.3 million, a 43.61% decrease from a year earlier, with the FY2025 full-year figure at -$162.5 million, down 25.47% from the prior year.
• Profit After Tax for Q1 2026 stood at -$53.1 million, down from -$46.1 million in the prior quarter.
• Over the last five years, Profit After Tax for OLMA reached as high as -$20.1 million in Q2 2023 and fell as low as -$53.1 million in Q1 2026.
• Historically, Profit After Tax has averaged -$32.3 million across 5 years, with a median of -$30.5 million in 2024.
• Across the five-year window, Profit After Tax slumped 104.99% in 2022 and soared 40.25% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$25.3 million in 2022, then dropped by 5.74% to -$26.8 million in 2023, then retreated by 25.38% to -$33.6 million in 2024, then sank by 37.22% to -$46.1 million in 2025, then declined by 15.26% to -$53.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$53.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.2 million in Q3 2025.